Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!

被引：73

作者：

Amaral, Leonard ^{[1
]}

Boeree, Martin J. ^{[2
,3
]}

Gillespie, Stephen H. ^{[4
]}

Udwadia, Zarir F. ^{[5
]}

van Soolingen, Dick ^{[6
]}

机构：

[1] Univ Nova Lisboa, Unit Mycobacteriol UPMM, Inst Hyg & Trop Med, P-1200 Lisbon, Portugal

[2] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands

[3] ULC Dekkerswald, Nijmegen, Netherlands

[4] UCL, Ctr Med Microbiol, London, England

[5] Hinduja Hosp & Res Ctr, Bombay, Maharashtra, India

[6] Natl Inst Publ Hlth & Environm, TB Reference Lab, NL-3720 BA Bilthoven, Netherlands

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2010年 / 35卷 / 06期

基金：

英国医学研究理事会;

关键词：

Pulmonary tuberculosis; Multidrug-resistant TB; Extensively drug-resistant TB; EMERGENCE;

D O I：

10.1016/j.ijantimicag.2009.12.019

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Thioridazine (TDZ) has been shown to have in vitro activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, to promote the killing of intracellular MDR and XDR strains and to cure the mouse of antibiotic-susceptible and -resistant pulmonary tuberculosis (TB) infections. Recently, TDZ was used to cure 10 of 12 XDR-TB patients in Buenos Aires, Argentina. At the time of writing, it is being used for the therapy of non-antibiotic-responsive terminal XDR-TB patients in Mumbai, India, on the basis of compassionate therapy and although it is too early to determine a cure, the patients have improved appetite, weight gain, are afebrile and free of night sweats, and their radiological picture shows great improvement. Because XDR-TB is essentially a terminal disease in many areas of the world and no new effective agents have yet to yield successful clinical trials, global clinical trials for the therapy of XDR-TB are urgently required. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

引用

页码：524 / 526

页数：3

共 15 条

[1]

ABBATE E, 2007, REV ARGENTINA MED RE, V1, P19

[2] Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis [J].

Amaral, L ;

Kristiansen, JE ;

Abebe, LS ;

Millett, W .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (06) :1049-1053

[3] Risk factors for multidrug resistant tuberculosis in Europe: a systematic review [J].

Faustini, A ;

Hall, AJ ;

Perucci, CA .

THORAX, 2006, 61 (02) :158-163

[4] THE EMERGENCE OF DRUG-RESISTANT TUBERCULOSIS IN NEW-YORK-CITY [J].

FRIEDEN, TR ;

STERLING, T ;

PABLOSMENDEZ, A ;

KILBURN, JO ;

CAUTHEN, GM ;

DOOLEY, SW .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (08) :521-526

[5]

Martins M, 2007, IN VIVO, V21, P771

[6] SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB) [J].

Martins, Marta ;

Viveiros, Miguel ;

Ramos, Jorge ;

Couto, Isabel ;

Molnar, Joseph ;

Boeree, Martin ;

Amaral, Leonard .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 33 (05) :479-482

[7] Clinical development of anti-tuberculosis drugs [J].

Mitchison, D. A. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (03) :494-495

[8] Randomized trials to optimize treatment of multidrug-resistant tuberculosis [J].

Mitnick, Carole D. ;

Castro, Kenneth G. ;

Harrington, Mark ;

Sacks, Leonard V. ;

Burman, William .

PLOS MEDICINE, 2007, 4 (11) :1730-1734

[9]

Munsiff SS, 2002, EMERG INFECT DIS, V8, P1230

[10] Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis [J].

Ordway, D ;

Viveiros, M ;

Leandro, C ;

Bettencourt, R ;

Almeida, J ;

Martins, M ;

Kristiansen, JE ;

Molnar, J ;

Amaral, L .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (03) :917-922

← 1 2 →